Curriculum Vitaes
Profile Information
- Affiliation
- Fujita Health University
- Degree
- M.D.Ph.D.(Mie University)
- J-GLOBAL ID
- 201801000601870256
- researchmap Member ID
- B000316559
Research Areas
1Research History
2-
Sep, 2021 - Present
-
Jul, 2020 - Aug, 2021
Committee Memberships
5Papers
216-
Asian journal of surgery, Jul 20, 2024 Peer-reviewedOBJECTIVE: The risk factors for residual liver recurrence after resection of colorectal cancer liver metastases were analyzed separately for synchronous and metachronous metastases. METHODS: This retrospective study included 236 patients (139 with synchronous and 97 with metachronous lesions) who underwent initial surgery for colorectal cancer liver metastases from April 2010 to December 2021 at the Fujita Health University Hospital. We performed univariate and multivariate analyses of risk factors for recurrence based on clinical background. RESULTS: Univariate analysis of synchronous liver metastases identified three risk factors: positive lymph nodes (p = 0.018, HR = 2.067), ≥3 liver metastases (p < 0.001, HR = 2.382), and use of adjuvant chemotherapy (p = 0.013, HR = 0.560). Multivariate analysis identified the same three factors. For metachronous liver metastases, univariate and multivariate analysis identified ≥3 liver metastases as a risk factor (p = 0.002, HR = 2.988); however, use of adjuvant chemotherapy after hepatic resection was not associated with a lower risk of recurrence for metachronous lesions. Inverse probability of treatment weighting analysis of patients with these lesions with or without adjuvant chemotherapy after primary resection showed that patients with metachronous liver metastases who did not receive this treatment had fewer recurrences when adjuvant therapy was administered after subsequent liver resection, although the difference was not significant. Patients who received adjuvant chemotherapy after hepatic resection had less recurrence but less benefit from this treatment. CONCLUSION: Risk factors for liver recurrence after resection of synchronous liver metastases were positive lymph nodes, ≥3 liver metastases, and no postoperative adjuvant chemotherapy. Adjuvant chemotherapy is recommended after hepatic resection of synchronous liver metastases.
Misc.
592-
日本大腸肛門病学会雑誌, 61(9) 627-627, Sep, 2008
-
WS-7-7 直腸癌術前化学放射線療法における照射スケジュールの工夫(ワークショップ7 術前放射線療法,高用量化学療法施行例に対する消化器癌手術 : 私はこうしている,第63回日本消化器外科学会総会)日本消化器外科学会雑誌, 41(7) 1078-1078, Jul 1, 2008
-
日本消化器外科学会雑誌, 41(7) 1027-1027, Jul 1, 2008
-
日本消化器外科学会雑誌, 41(7) 1503-1503, Jul 1, 2008
-
日本消化器外科学会雑誌, 41(7) 1548-1548, Jul 1, 2008
-
日本消化器外科学会雑誌, 41(7) 1204-1204, Jul 1, 2008
-
日本外科学会雑誌, 109(2) 634-634, Apr 25, 2008
-
日本外科学会雑誌, 109(2) 490-490, Apr 25, 2008
-
日本臨床外科学会雑誌, 68(増刊) 394-394, Nov, 2007
-
日本大腸肛門病学会雑誌, 60(9) 549-549, Sep, 2007
-
日本癌学会総会記事, 66回 544-544, Aug, 2007
-
P-2-611 De-escalation chemotherapyにて良好な経過を得ている虫垂癌腹膜播種の1例(大腸・肛門 虫垂腫瘍1,一般演題(ポスター),第62回日本消化器外科学会定期学術総会)日本消化器外科学会雑誌, 40(7) 1415-1415, Jul 1, 2007
-
日本消化器外科学会雑誌, 40(7) 1411-1411, Jul 1, 2007
-
日本消化器外科学会雑誌, 40(7) 1304-1304, Jul 1, 2007
-
日本消化器外科学会雑誌, 40(7) 1168-1168, Jul 1, 2007
-
日本外科学会雑誌, 108(2) 559-559, Mar 10, 2007
-
日本外科学会雑誌, 108 146-146, Mar 10, 2007
Presentations
189-
日本内視鏡外科学会雑誌, Mar, 2021, (一社)日本内視鏡外科学会